SeaStar Medical presented positive real-world data from its QUELIMMUNE SAVE Registry and new mechanistic insights into its Selective Cytopheretic Device at the AKI & CRRT 2026 conference. The data reinforce clinical evidence for the device's mechanism of action and may support broader clinical adoption in acute kidney injury/CRRT settings. No financial metrics, regulatory approvals, or commercial milestones were announced.
SeaStar Medical presented positive real-world data from its QUELIMMUNE SAVE Registry and new mechanistic insights into its Selective Cytopheretic Device at the AKI & CRRT 2026 conference. The data reinforce clinical evidence for the device's mechanism of action and may support broader clinical adoption in acute kidney injury/CRRT settings. No financial metrics, regulatory approvals, or commercial milestones were announced.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
